Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
暂无分享,去创建一个
G. Yancopoulos | M. Suárez-Fariñas | N. Graham | G. Pirozzi | J. Krueger | I. Cardinale | Xuan Li | A. Kostic | E. Guttman‐Yassky | J. Ming | J. Hamilton | A. Radin | N. Dhingra | A. Kostić | E. Guttman-Yassky
[1] M. Suárez-Fariñas,et al. Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. , 2014, The Journal of allergy and clinical immunology.
[2] D. Leung,et al. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. , 2014, The Journal of allergy and clinical immunology.
[3] M. Kubo,et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. , 2014, The Journal of investigative dermatology.
[4] T. Bieber,et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.
[5] J. Bouwstra,et al. TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. , 2014, The Journal of investigative dermatology.
[6] G. Barton,et al. Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis , 2014, The Journal of allergy and clinical immunology.
[7] M. Suárez-Fariñas,et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. , 2014, The Journal of allergy and clinical immunology.
[8] Nicholas Gulati,et al. Mechanisms of contact sensitization offer insights into the role of barrier defects versus intrinsic immune abnormalities as drivers of atopic dermatitis , 2013, The Journal of investigative dermatology.
[9] M. Suárez-Fariñas,et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. , 2013, The Journal of allergy and clinical immunology.
[10] S. Wenzel,et al. Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.
[11] V. Shi,et al. IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis. , 2013, Cytokine.
[12] M. Suárez-Fariñas,et al. Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. , 2013, The Journal of allergy and clinical immunology.
[13] M. Suárez-Fariñas,et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. , 2012, The Journal of allergy and clinical immunology.
[14] A. Bowcock,et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. , 2011, The Journal of allergy and clinical immunology.
[15] U. Sivaprasad,et al. Th2 Cytokines and Atopic Dermatitis. , 2011, Journal of clinical & cellular immunology.
[16] M. Boguniewicz,et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation , 2011, Immunological reviews.
[17] J. Krueger,et al. Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. , 2011, The Journal of allergy and clinical immunology.
[18] J. Krueger,et al. Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. , 2011, The Journal of allergy and clinical immunology.
[19] A. Bowcock,et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. , 2011, The Journal of allergy and clinical immunology.
[20] M. Kaplan,et al. Transcriptional regulation by STAT6 , 2011, Immunologic research.
[21] M. Chren,et al. Quality-of-life outcomes and measurement in childhood atopic dermatitis. , 2010, Immunology and allergy clinics of North America.
[22] M. Kaplan,et al. IL-4 Regulates Skin Homeostasis and the Predisposition toward Allergic Skin Inflammation , 2010, The Journal of Immunology.
[23] J. Dieris-Hirche,et al. Suizidgedanken, Angst und Depression bei erwachsenen Neurodermitikern , 2009, Der Hautarzt.
[24] J. Redzic,et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. , 2008, The Journal of investigative dermatology.
[25] N. Korman,et al. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. , 2008, Journal of the American Academy of Dermatology.
[26] L. Doward,et al. Quality of life of children with atopic dermatitis and their families , 2008, Current opinion in allergy and clinical immunology.
[27] M. Boguniewicz,et al. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. , 2008, Clinical immunology.
[28] K. Kaulback,et al. The Socioeconomic Impact of Atopic Dermatitis in the United States: A Systematic Review , 2008, Pediatric dermatology.
[29] J. Fowler,et al. The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective. , 2007, Managed care interface.
[30] K. Barnes,et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. , 2007, The Journal of allergy and clinical immunology.
[31] Jon M Hanifin,et al. A Population‐Based Survey of Eczema Prevalence in the United States , 2007, Dermatitis : contact, atopic, occupational, drug.
[32] Erin G Harper,et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. , 2007, Journal of the American Academy of Dermatology.
[33] H. Kimata. Prevalence of suicidal ideation in patients with atopic dermatitis. , 2006, Suicide & life-threatening behavior.
[34] Mayte Suárez-Fariñas,et al. Harshlight: a "corrective make-up" program for microarray chips , 2005, BMC Bioinformatics.
[35] Rafael A. Irizarry,et al. A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .
[36] H. Wulf,et al. Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. , 2004, Acta dermato-venereologica.
[37] K. Izuhara,et al. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. , 2002, Current drug targets. Inflammation and allergy.
[38] M. Graeber,et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.
[39] A. Y. Finlay,et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis , 1991, The Lancet.